-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] On June 1, the biopharmaceutical sector rebounded slightly, and many pharmaceutical stocks in the sector hit the daily limit, such as Zejing Pharmaceuticals, Sailong Pharmaceuticals,e.
Among them, Zejing Pharmaceutical opened the daily limit at a rapid rate today, and the stock has risen by the limit once in the past ye.
On the news, Zejing Pharma announced on the evening of May 31 that the clinical trial application for jacktinib hydrochloride tablets independently developed by the company was accept.
According to reports, jacktinib hydrochloride is a new type of JAK inhibitor drug independently developed by Zejing Phar.
The drug has a significant inhibitory effect on multiple Janus kinases including JAK1, JAK2, JAK3 and TYKPharmacodynamics and clinical research results have shown that it can significantly inhibit the occurrence and development of various immune-inflammatory diseas.
However, the company also said that there is still uncertainty as to whether the application will be approv.
It is worth mentioning that Jacktinib hydrochloride tablets are currently conducting clinical studies on multiple inflammatory diseases or fibrotic diseases, including myelofibrosis (phase III), ruxolitinib-intolerant myelofibrosis (II.
Phase II registration clinical trial), ruxolitinib relapsed/refractory myelofibrosis (phase IIB clinical trial), severe alopecia areata (phase III), ankylosing spondylitis (phase II), moderate to severe atopic dermatitis (phase II) ), idiopathic pulmonary fibrosis (stage II), graft-versus-host disease (stage II), and moderate to severe plaque psoriasis (stage I.
According to public information, Zejing Pharma is an innovation-driven chemical and biological new drug research and development enterprise focusing on multiple therapeutic areas such as tumors, hemorrhagic and blood diseases, hepatobiliary diseases and immune-inflammatory diseas.
The 2021 annual report shows that Zejing Pharmaceutical will achieve revenue of 190 million yuan in 2021, a year-on-year increase of 5819%, but the net profit attributable to the parent will suffer a substantial loss of 451 million yuan, mainly because the company will further increase its research and development expenditure in 2021, investing more than 500 million yu.
A year-on-year increase of 613%; at the same time, the company is in the pre-expansion stage of drug listing and commercialization, and needs to invest a lot of pre-market expansion and academic promotion activiti.
In addition to Zejing Pharmaceutical, today's Sailong Pharmaceutical's intraday daily limit, as of 10:39, the stock rose more than 4%, the transaction was 961 million yuan, and the turnover rate was 1
On the news, the company Sailong Pharmaceutical announced on May 25 that Tang Lin, one of the company's controlling shareholders and actual controllers (holding 10,001,800 shares of the company, accounting for 68% of the company's total share capital) and shareholders holding more than 5% of the shares Zhuhai Hengqin New Area Sailong Juzhi Investment .
, L.
(holding 19455 million shares of the company, accounting for 06% of the company's total share capital) due to its own capital needs, plans to conduct centralized bidding within 6 months after 15 trading days from the date of announcement disclosure The two shareholders will reduce their holdings of the company's shares by no more than 76 million shares each (accounting for 1% of the company's total share capital); the two shareholders will reduce their holdings by no more than 52 million shares, accounting for about 2% of the company's total share capit.
The announcement shows that Tang Lin and the company's controlling shareholder, actual controller, and chairman Cai Nangui are husband and wi.
Cai Nangui holds 90169 million shares of the company, accounting for 515% of the company's total share capit.
Cai Nangui and Tang Lin have not reduced their holdings in the company since the company's stock listi.
shar.
According to the data, Sialon Pharmaceutical is a domestic neuroprotective agent manufacturer, mainly engaged in the research and development of pharmaceutical raw materials and preparatio.
The 2021 annual report shows that the company achieved an operating income of 247 million yuan, a year-on-year increase of 1073%; the net profit attributable to shareholders of the listed company was a loss of 23414 million yuan, a significant year-on-year decrea.
It is worth mentioning that during the reporting period, the company's new products have achieved certain resul.
For example, argatroban injection and tranexamic acid injection won the bid for the "eight provinces and two districts" centralized drug procurement, aspartic acid bird Amino acid injection won the bid of Lujin Inter-Provincial Alliance for centralized procurement, and tigecycline for injection won the bid of Fujian provincial centralized procurement,e.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Click to enter the exhibition page
Among them, Zejing Pharmaceutical opened the daily limit at a rapid rate today, and the stock has risen by the limit once in the past ye.
On the news, Zejing Pharma announced on the evening of May 31 that the clinical trial application for jacktinib hydrochloride tablets independently developed by the company was accept.
According to reports, jacktinib hydrochloride is a new type of JAK inhibitor drug independently developed by Zejing Phar.
The drug has a significant inhibitory effect on multiple Janus kinases including JAK1, JAK2, JAK3 and TYKPharmacodynamics and clinical research results have shown that it can significantly inhibit the occurrence and development of various immune-inflammatory diseas.
However, the company also said that there is still uncertainty as to whether the application will be approv.
It is worth mentioning that Jacktinib hydrochloride tablets are currently conducting clinical studies on multiple inflammatory diseases or fibrotic diseases, including myelofibrosis (phase III), ruxolitinib-intolerant myelofibrosis (II.
Phase II registration clinical trial), ruxolitinib relapsed/refractory myelofibrosis (phase IIB clinical trial), severe alopecia areata (phase III), ankylosing spondylitis (phase II), moderate to severe atopic dermatitis (phase II) ), idiopathic pulmonary fibrosis (stage II), graft-versus-host disease (stage II), and moderate to severe plaque psoriasis (stage I.
According to public information, Zejing Pharma is an innovation-driven chemical and biological new drug research and development enterprise focusing on multiple therapeutic areas such as tumors, hemorrhagic and blood diseases, hepatobiliary diseases and immune-inflammatory diseas.
The 2021 annual report shows that Zejing Pharmaceutical will achieve revenue of 190 million yuan in 2021, a year-on-year increase of 5819%, but the net profit attributable to the parent will suffer a substantial loss of 451 million yuan, mainly because the company will further increase its research and development expenditure in 2021, investing more than 500 million yu.
A year-on-year increase of 613%; at the same time, the company is in the pre-expansion stage of drug listing and commercialization, and needs to invest a lot of pre-market expansion and academic promotion activiti.
In addition to Zejing Pharmaceutical, today's Sailong Pharmaceutical's intraday daily limit, as of 10:39, the stock rose more than 4%, the transaction was 961 million yuan, and the turnover rate was 1
On the news, the company Sailong Pharmaceutical announced on May 25 that Tang Lin, one of the company's controlling shareholders and actual controllers (holding 10,001,800 shares of the company, accounting for 68% of the company's total share capital) and shareholders holding more than 5% of the shares Zhuhai Hengqin New Area Sailong Juzhi Investment .
, L.
(holding 19455 million shares of the company, accounting for 06% of the company's total share capital) due to its own capital needs, plans to conduct centralized bidding within 6 months after 15 trading days from the date of announcement disclosure The two shareholders will reduce their holdings of the company's shares by no more than 76 million shares each (accounting for 1% of the company's total share capital); the two shareholders will reduce their holdings by no more than 52 million shares, accounting for about 2% of the company's total share capit.
The announcement shows that Tang Lin and the company's controlling shareholder, actual controller, and chairman Cai Nangui are husband and wi.
Cai Nangui holds 90169 million shares of the company, accounting for 515% of the company's total share capit.
Cai Nangui and Tang Lin have not reduced their holdings in the company since the company's stock listi.
shar.
According to the data, Sialon Pharmaceutical is a domestic neuroprotective agent manufacturer, mainly engaged in the research and development of pharmaceutical raw materials and preparatio.
The 2021 annual report shows that the company achieved an operating income of 247 million yuan, a year-on-year increase of 1073%; the net profit attributable to shareholders of the listed company was a loss of 23414 million yuan, a significant year-on-year decrea.
It is worth mentioning that during the reporting period, the company's new products have achieved certain resul.
For example, argatroban injection and tranexamic acid injection won the bid for the "eight provinces and two districts" centralized drug procurement, aspartic acid bird Amino acid injection won the bid of Lujin Inter-Provincial Alliance for centralized procurement, and tigecycline for injection won the bid of Fujian provincial centralized procurement,e.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Click to enter the exhibition page
